Loading...

Top 100 Innovators in Germany

Katja has been selected by the German finance newspaper Handelsblatt as one of the top 100 innovators in Germany
"German innovators tend not to shout from the hilltops when they come up with things that have the potential to change the world. But Handelsblatt sought out Germany’s 100 smartest innovators - amid many more...Then there’s Katja Schenke-Layland, a 39-year-old biologist at the Fraunhofer Institute in Stuttgart. She is working on ways to produce heart valves or other tissue from hybrid materials, like synthetic polymers and biological proteins. The benefit of the approach is that this hybrid tissue grows with the bodies into which it is implanted. This is especially helpful for children, because it reduces the need for multiple operations."
Handelsblatt Staff
Full article is Here

Our Work

Elucidate - translate - design - build - verify

About Katja

Prof. Dr Katja Schenke-Layland

Professor at the Women's University Hospital Tubingen

Katja is the Professor of Medical Technologies and Regenerative Medicine in the Department for Women's Health at the University Women's Hospital Tubingen and Deputy Student Dean of the Medical Technology program at the University of Tubingen.

Women's Hospital Tübingen

Director and Department Head at the Fraunhofer IGB Stuttgart

Katja is the Interim Director (2016) of the Fraunhofer Institute for Interfacial Engineering and Biotechnology (IGB) and Department Head of the Department of Cell and Tissue Engineering

Fraunhofer IGB Stuttgart

Our Lab by the Numbers since 2011

A bit of information on our publications
288
Total Impact Points
58
Total Publications
10
Publication Pipeline

Lab News

Latest and Greatest

17
March

Katja - "The 100 Smartest Innovators in Germany"

German innovators tend not to shout from the hilltops so the Handelsblatt newspaper (Germany's Wall Street Journal) sought out Germany’s 100 smartest innovators ...

14
Dec

Katja at "10 Jahre Pakt für Forschung & Innovation"

Katja joined Johanna Wank (German Minister for Education and Research), Eva Quante-Brandt, Anja Kohl, Andreas Busch and Matthias Kleiner in a panel disucssion ...

9
Dec

Acta Biomaterialia paper by Brauchle et al

Fibrillin microfibrils and elastic fibers are critical determinants of elastic tissues where they define as tissue-specific architectures vital mechanical properties ...

Studienpreis 2015
Video report of Svenja's work (German)

Latest Papers

The latest original articles from the lab

Actinic Keratosis’ (AKs) are small skin lesions that are related to a prolonged sun-damage, which can develop into invasive squamous cell carcinoma (SCC) when left untreated. Effective, specific and well tolerable therapies to cure AKs are still of great interest. Diclofenac (DCF) is the current gold standard for the local treatment of AKs in terms of costs, effectiveness, side effects and tolerability. In this work, an electrospun polylactic acid (PLA) scaffold loaded with a synthetic DCF prodrug was developed and characterized. Specifically, the prodrug was successfully synthetized by binding DCF to a glycine residue via solid phase peptide synthesis (SPPS) and then incorporated in an electrospun PLA scaffold. The drug encapsulation was verified using multiphoton microscopy (MPM) and its scaffold release was spectrophotometrically monitored and confirmed with MPM. The scaffold was further characterized with scanning electron microscopy (SEM), tensile testing and contact angle measurements. Its biocompatibility was verified by performing a cell proliferation assay and compared to PLA scaffolds containing the same amount of DCF sodium salt (DCFONa). Finally, the effect of the electrospun scaffolds on human dermal fibroblasts (HDFs) morphology and metabolism was investigated by combining MPM with fluorescence lifetime imaging microscopy (FLIM). The obtained results suggest that the obtained scaffold could be suitable for the controlled and targeted delivery of the synthesized prodrug for the treatment of AKs.

Full Article Here